135 related articles for article (PubMed ID: 26122843)
41. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls.
Bosviel R; Michard E; Lavediaux G; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ
Clin Chim Acta; 2011 Jul; 412(15-16):1472-5. PubMed ID: 21557934
[TBL] [Abstract][Full Text] [Related]
42. The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - a prospective nation-wide study in Finland.
Kumpulainen S; Sankila R; Leminen A; Kuoppala T; Komulainen M; Puistola U; Hurme S; Hiekkanen H; Mäkinen J; Grénman S
Gynecol Oncol; 2009 Nov; 115(2):199-203. PubMed ID: 19695688
[TBL] [Abstract][Full Text] [Related]
43. Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma.
Beussel S; Hasenburg A; Bogatyreva L; Hauschke D; Werner M; Lassmann S
J Clin Pathol; 2012 Jan; 65(1):29-35. PubMed ID: 22011448
[TBL] [Abstract][Full Text] [Related]
44. No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
Vach W; Bergmann TK; Brøsen K
J Clin Oncol; 2008 Apr; 26(11):1903-4; author reply 1904-5. PubMed ID: 18398158
[No Abstract] [Full Text] [Related]
45. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts.
Topp MD; Hartley L; Cook M; Heong V; Boehm E; McShane L; Pyman J; McNally O; Ananda S; Harrell M; Etemadmoghadam D; Galletta L; Alsop K; Mitchell G; Fox SB; Kerr JB; Hutt KJ; Kaufmann SH; Australian Ovarian Cancer Study ; Swisher EM; Bowtell DD; Wakefield MJ; Scott CL
Mol Oncol; 2014 May; 8(3):656-68. PubMed ID: 24560445
[TBL] [Abstract][Full Text] [Related]
46. Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.
Markman M; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 2004 Oct; 95(1):109-13. PubMed ID: 15385118
[TBL] [Abstract][Full Text] [Related]
47. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes.
Wang YK; Bashashati A; Anglesio MS; Cochrane DR; Grewal DS; Ha G; McPherson A; Horlings HM; Senz J; Prentice LM; Karnezis AN; Lai D; Aniba MR; Zhang AW; Shumansky K; Siu C; Wan A; McConechy MK; Li-Chang H; Tone A; Provencher D; de Ladurantaye M; Fleury H; Okamoto A; Yanagida S; Yanaihara N; Saito M; Mungall AJ; Moore R; Marra MA; Gilks CB; Mes-Masson AM; McAlpine JN; Aparicio S; Huntsman DG; Shah SP
Nat Genet; 2017 Jun; 49(6):856-865. PubMed ID: 28436987
[TBL] [Abstract][Full Text] [Related]
48. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
49. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors.
Veeck J; Ropero S; Setien F; Gonzalez-Suarez E; Osorio A; Benitez J; Herman JG; Esteller M
J Clin Oncol; 2010 Oct; 28(29):e563-4; author reply e565-6. PubMed ID: 20679605
[No Abstract] [Full Text] [Related]
50. Pharmacogenomics of taxane/platinum therapy in ovarian cancer.
Marsh S
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S30-4. PubMed ID: 19955911
[TBL] [Abstract][Full Text] [Related]
51. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.
Kreuzinger C; Gamperl M; Wolf A; Heinze G; Geroldinger A; Lambrechts D; Boeckx B; Smeets D; Horvat R; Aust S; Hamilton G; Zeillinger R; Cacsire Castillo-Tong D
Cancer Lett; 2015 Jul; 362(2):218-28. PubMed ID: 25862976
[TBL] [Abstract][Full Text] [Related]
52. Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer.
Zhou M; Sun Y; Sun Y; Xu W; Zhang Z; Zhao H; Zhong Z; Sun J
Oncotarget; 2016 May; 7(22):32433-48. PubMed ID: 27074572
[TBL] [Abstract][Full Text] [Related]
53. Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
Kang HJ; Chun SM; Kim KR; Sohn I; Sung CO
PLoS One; 2013; 8(8):e72609. PubMed ID: 23967324
[TBL] [Abstract][Full Text] [Related]
54. MLH1 Is a Prognostic Biomarker for Serous Ovarian Cancer Treated With Platinum- and Taxane-based Chemotherapy.
Kawashima N; Yoshida H; Miwa M; Fujiwara K
Anticancer Res; 2019 Oct; 39(10):5505-5513. PubMed ID: 31570444
[TBL] [Abstract][Full Text] [Related]
55. A seven-gene prognostic model for platinum-treated ovarian carcinomas.
Sabatier R; Finetti P; Bonensea J; Jacquemier J; Adelaide J; Lambaudie E; Viens P; Birnbaum D; Bertucci F
Br J Cancer; 2011 Jul; 105(2):304-11. PubMed ID: 21654678
[TBL] [Abstract][Full Text] [Related]
56. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer.
Jeong W; Kim SB; Sohn BH; Park YY; Park ES; Kim SC; Kim SS; Johnson RL; Birrer M; Bowtell DSL; Mills GB; Sood A; Lee JS
Anticancer Res; 2014 Feb; 34(2):811-817. PubMed ID: 24511017
[TBL] [Abstract][Full Text] [Related]
57. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response.
Zervantonakis IK; Iavarone C; Chen HY; Selfors LM; Palakurthi S; Liu JF; Drapkin R; Matulonis U; Leverson JD; Sampath D; Mills GB; Brugge JS
Nat Commun; 2017 Aug; 8(1):365. PubMed ID: 28848242
[TBL] [Abstract][Full Text] [Related]
58. Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.
Ring BZ; Murali R; Soslow RA; Bowtell DDL; Fereday S; deFazio A; Traficante N; Kennedy CJ; Brand A; Sharma R; Harnett P; Samimi G;
Cancer Epidemiol Biomarkers Prev; 2018 Jun; 27(6):680-688. PubMed ID: 29531130
[No Abstract] [Full Text] [Related]
59. miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study.
Panoutsopoulou K; Avgeris M; Mavridis K; Dreyer T; Dorn J; Obermayr E; Reinthaller A; Michaelidou K; Mahner S; Vergote I; Vanderstichele A; Braicu I; Sehouli J; Zeillinger R; Magdolen V; Scorilas A
Carcinogenesis; 2020 Jun; 41(4):442-451. PubMed ID: 31586203
[TBL] [Abstract][Full Text] [Related]
60. Network Pharmacology-Based and Clinically Relevant Prediction of the Potential Targets of Chinese Herbs in Ovarian Cancer Patients.
Sun J; Liu J; Liu D; Wu X
Biomed Res Int; 2020; 2020():8965459. PubMed ID: 33150184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
